Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.12 - $0.3 $5,931 - $14,828
-49,428 Reduced 14.6%
289,094 $37,000
Q4 2022

Feb 10, 2023

SELL
$0.15 - $0.63 $116,592 - $489,688
-777,284 Reduced 69.66%
338,522 $54,000
Q3 2022

Nov 14, 2022

BUY
$0.52 - $3.08 $7,776 - $46,058
14,954 Added 1.36%
1,115,806 $726,000
Q1 2022

May 13, 2022

SELL
$3.54 - $8.3 $150,425 - $352,691
-42,493 Reduced 3.72%
1,100,852 $4.45 Million
Q4 2021

Feb 14, 2022

SELL
$7.69 - $19.66 $11,358 - $29,037
-1,477 Reduced 0.13%
1,143,345 $9.16 Million
Q3 2021

Nov 12, 2021

BUY
$12.22 - $21.28 $2.41 Million - $4.2 Million
197,521 Added 20.85%
1,144,822 $22.1 Million
Q2 2021

Aug 13, 2021

BUY
$9.0 - $15.94 $8.53 Million - $15.1 Million
947,301 New
947,301 $13.1 Million

Others Institutions Holding PLXP

About PLx Pharma Inc.


  • Ticker PLXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,137,700
  • Description
  • PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...
More about PLXP
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.